PS1028 ALLG APML5: A COMPARATIVE BIOAVAILABILITY STUDY OF ENCAPSULATED ORAL ARSENIC TRIOXIDE AND INTRAVENOUS ARSENIC TRIOXIDE IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA UNDERGOING CONSOLIDATION THERAPY
Harry Iland(Royal Prince Alfred Hospital), C. Risteski(Princess Margaret Cancer Centre), Rosemary Harrup(University of Tasmania), Liane Khoo(The University of Sydney), Stephen Lane(Novartis (United States)), Andrew H. Wei(The Royal Melbourne Hospital), Sam Yuen(Calvary Mater Newcastle Hospital), Robin Gasiorowski(The University of Sydney), Paula Marlton(The University of Queensland), Christian Bryant(Royal Prince Alfred Hospital), John Reynolds(The Alfred Hospital), Alan V. Boddy(University of South Australia)
Cited by 1
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
|Journal of Clinical Oncology|1999|960
The genomic landscape of hypodiploid acute lymphoblastic leukemia
|Nature Genetics|2013|737